

Faculty:

Prof. Dr. med. Björn Chapuy
*Medical clinic for Hematology, Oncology
and Tumor Immunology | CBF
Charité - University Medicine
Berlin, Germany*

Professor Andrés J. M. Ferreri, MD
*University Vita-Salute San Raffaele
Milan, Italy*

Dr. med. Johannes Düll
*Medical Clinic and Polyclinic II
University Hospital Würzburg
Würzburg, Germany*

Prof. Dr. med. Hermann Einsele
*Medical Clinic and Polyclinic II
University Hospital Würzburg
Würzburg, Germany*

Florian Eisele, MD
*Medical Clinic and Polyclinic II
University Hospital Würzburg
Würzburg, Germany*

Pieterella Lugtenburg MD, PhD
*Erasmus MC - Cancer Institute
Rotterdam, The Netherlands*

Dr. med. Michael Oertel
*Clinic for Radiotherapy - Radiooncology
University Clinic Münster
Münster, Germany*

Prof. Dr. med. Max Topp
*Medical Clinic and Polyclinic II
University Hospital Würzburg
Würzburg, Germany*

Dr. Jason R. Westin
*Department of Lymphoma - Myeloma,
Division of Cancer Medicine
University of Texas MD Anderson
Cancer Center
Houston, TX, USA*

Professor Pier Luigi Zinzani
*Department of Medical and Surgical
Sciences
Università di Bologna
Bologna, Italy*

Scientific Chair/Host

Dr. med. Johannes Düll

Venue:

Hotel Melchior Park
Am Galgenberg 49
97074 Würzburg
Germany
<https://t1p.de/melchior>

With the kind support of our sponsors



An event of:

Academy2 GmbH & Co. KG
Fürther Straße 33
90513 Zirndorf, Germany
www.academy2.de
www.cmeducation.de

The contents of this event are designed to be product and service neutral. The organizer confirms, that the scientific chair and the speakers will disclose potential conflicts of interest to the participants. The event is sponsored by the following: Incyte Biosciences Germany GmbH with an amount of 25.000€, Swedish Orphan Biovitrum GmbH, with an amount of 20.000€, AbbVie Deutschland GmbH & Co. KG with an amount of 18.000€, AstraZeneca GmbH with an amount of 10.000€, Gilead Sciences GmbH with an amount of 10.000€, Roche Pharma AG with an amount of 10.000€, BeiGene Germany GmbH with an amount of 10.000€, Bristol-Myers Squibb GmbH & Co. KGaA with an amount of 10.000€. The total expenses of the event amount to 113.000.00€.

*tbc: to be confirmed

INVITATION & PROGRAM

Insights in DLBCL: New Horizons 2025

Friday 09.05.2025

Saturday 10.05.2025

Live in Würzburg and online!

Register now!



To get to the registration, click on
the button or scan the QR code.

<https://qrco.de/DLBCL2025>

CME-certification is pending

Uniklinikum
Würzburg



Welcome letter

Dear colleagues!

Fortunately, the treatment landscape for aggressive lymphoma has undergone a revolution in the last few years. Current therapies have had an impact on first-line therapy. Immunotherapies such as CAR T-cells and bispecific antibodies are now used as standard of care from the second line onwards. As a result more and more colleagues are using these therapeutic options and thus generating a broad knowledge of the effectiveness and side effects of these therapies.

With our DLBCL congress we are happy to offer a platform where we all can exchange and develop ideas with colleagues and learn from each other. Whether on site in Würzburg or live online: we are looking forward to a highly informative and exciting event and a lively exchange with you!

Best regards,



Johannes Düll
Senior physician
Universitätsklinik Würzburg

Scientific Program

Friday, May 9th 2025

- | | |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| 15:00 - 15:15 | Welcome and introduction Prof. Dr. med. Hermann Einsele Dr. med. Johannes Düll |
| 15:15 - 16:00 | A lot of experience - treatment decisions in the first line - what is important for our Patients Professor Pier Luigi Zinzani |
| 16:00 - 16:45 | Methods to confirm success in DLBCL- PET and ctDNA- are we already there where we want? New methods new trial concepts? Dr. Jason R. Westin |
| 16:45 - 17:15 | CNS Lymphoma – Diagnostic and treatment – state of the art Professor Andrés J. M. Ferreri, MD |
| 17:15 - 17:45 | Coffee break |
| 17:45 - 18:15 | Radiotherapy in DLBCL – from bridge to CAR T to consolidation Dr. med. Michael Oertel |
| 18:15 - 19:30 | Immunotherapy in DLBCL long term results- efficacy and toxicities Prof. Dr. med. Max Topp |
| 19:30 - 21:30 | Dinner |

*tbc: to be confirmed

Saturday, May 10th 2025

- | | |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| 9:00 - 10:00 | CAR T in second line with focus on bridge to CAR T concepts Prof. Dr. med. Björn Chapuy |
| 10:00 - 10:45 | Bispecs: mono vs combinations: what can we expect Professor Pieterella Lugtenburg, MD, PhD |
| 10:45 - 11:00 | Coffee break |
| 11:00 - 12:00 | Case studies (second line/third line and beyond) with focus on treatment decision and sequencing of therapies Florian Eisele, MD |
| 12:00 - 12:30 | What's hot and what's not? DLBCL-specific highlights of ASH 2024 TBD |
| 12:30 | Conclusion and Farewell Dr. med. Johannes Düll |

Register now!



<https://qrco.de/DLBCL2025>